Logo image of IMAB

I-MAB-SPONSORED ADR (IMAB) Stock Overview

NASDAQ:IMAB - US44975P1030 - ADR

4.16 USD
-0.09 (-2.12%)
Last: 8/29/2025, 4:11:39 PM
4.16 USD
0 (0%)
After Hours: 8/29/2025, 4:11:39 PM

IMAB Key Statistics, Chart & Performance

Key Statistics
52 Week High5.9
52 Week Low0.6
Market Cap339.71M
Shares81.66M
Float24.20M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.43
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-17 2020-01-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IMAB short term performance overview.The bars show the price performance of IMAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300

IMAB long term performance overview.The bars show the price performance of IMAB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200

The current stock price of IMAB is 4.16 USD. In the past month the price increased by 111.44%. In the past year, price increased by 276.11%.

I-MAB-SPONSORED ADR / IMAB Daily stock chart

IMAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About IMAB

Company Profile

IMAB logo image I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Company Info

I-MAB-SPONSORED ADR

Suite 400, 2440 Research Blvd

Rockville MARYLAND 201210 US

CEO: Joan Huaqiong Shen

Employees: 32

IMAB Company Website

IMAB Investor Relations

Phone: 13016702800

I-MAB-SPONSORED ADR / IMAB FAQ

What is the stock price of I-MAB-SPONSORED ADR today?

The current stock price of IMAB is 4.16 USD. The price decreased by -2.12% in the last trading session.


What is the ticker symbol for I-MAB-SPONSORED ADR stock?

The exchange symbol of I-MAB-SPONSORED ADR is IMAB and it is listed on the Nasdaq exchange.


On which exchange is IMAB stock listed?

IMAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for I-MAB-SPONSORED ADR stock?

11 analysts have analysed IMAB and the average price target is 6.32 USD. This implies a price increase of 52.02% is expected in the next year compared to the current price of 4.16. Check the I-MAB-SPONSORED ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is I-MAB-SPONSORED ADR worth?

I-MAB-SPONSORED ADR (IMAB) has a market capitalization of 339.71M USD. This makes IMAB a Small Cap stock.


How many employees does I-MAB-SPONSORED ADR have?

I-MAB-SPONSORED ADR (IMAB) currently has 32 employees.


What are the support and resistance levels for I-MAB-SPONSORED ADR (IMAB) stock?

I-MAB-SPONSORED ADR (IMAB) has a support level at 4.24. Check the full technical report for a detailed analysis of IMAB support and resistance levels.


Should I buy I-MAB-SPONSORED ADR (IMAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does I-MAB-SPONSORED ADR (IMAB) stock pay dividends?

IMAB does not pay a dividend.


What is the Price/Earnings (PE) ratio of I-MAB-SPONSORED ADR (IMAB)?

I-MAB-SPONSORED ADR (IMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).


What is the Short Interest ratio of I-MAB-SPONSORED ADR (IMAB) stock?

The outstanding short interest for I-MAB-SPONSORED ADR (IMAB) is 2.01% of its float. Check the ownership tab for more information on the IMAB short interest.


IMAB Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to IMAB. When comparing the yearly performance of all stocks, IMAB is one of the better performing stocks in the market, outperforming 99.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IMAB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IMAB. IMAB has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMAB Financial Highlights

Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 89.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.22%
ROE -19.14%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%85.65%
Sales Q2Q%N/A
EPS 1Y (TTM)89.81%
Revenue 1Y (TTM)-100%

IMAB Forecast & Estimates

11 analysts have analysed IMAB and the average price target is 6.32 USD. This implies a price increase of 52.02% is expected in the next year compared to the current price of 4.16.


Analysts
Analysts83.64
Price Target6.32 (51.92%)
EPS Next Y69.91%
Revenue Next YearN/A

IMAB Ownership

Ownership
Inst Owners13.08%
Ins Owners0.79%
Short Float %2.01%
Short Ratio0.24